Boston Therapeutics (OTCQB:BTHE) CEO Interview Series


Boston Therapeutics
CEO: David Platt


WSA: Good day from Wall Street, this is Juan Costello, Senior Analyst at the Wall Street Analyzer.  Joining us today is David Platt, CEO for Boston Therapeutics.  The company trades on the OTCQB, Ticker symbol is BTHE.  Thanks for joining us today, David.

David Platt:  Thank you for having me.

Juan Costello:  Great.  Anytime.  So, yes, starting off for some of our listeners that didn’t catch our previous interview, can you give us a history and overview of the company?

David Platt:  Thank you, very good.  Boston Therapeutics was founded several years ago on the basic premise of exploring safe and effective carbohydrate chemistry to bring products to the healthcare market worldwide.  Our vision early on was to seek early foreign partners to both support and accelerate the development of our very safe and effective material that are patent protected.  This development effort has served us well and has allowed to us to advance despite the capital market situation.  With the potential of revenue from our market entry, we can be prepared to access a broader reach of the investment population.

WSA: Great.  And so bring us up to speed on some of your news since we last spoke six months ago including updates on SUGARDOWN and the BTI-320.

David Platt:  Very good in our company, the product called BTI-320, is addressing the need for lowering blood sugar or blocking sugars from getting into the bloodstream.  So we are in a clinical trial.  We just finished the equipment and we are in the process of summarizing the data on the clinical trial.

WSA: And so, what are some of the key trends that you’re focusing on right now in the sector and how are you positioning the company to capitalize?

David Platt:  Diabetes is a explosive health issue around the use and work that some people call abuse of sugar in our fast food, desserts, and drinks.  This singular item can bulk up the sugar – it actually can bulk up the healthcare system worldwide, the excess sugar for the obesity, heart disease and diabetes and all driven by calories from deposits and excess sugar that we take in.  So you can’t change the world overnight maybe even in a decade, but you can reduce the limit os an individuals own sugar intake.  It is estimated that the upward of 20%, 30% of the industrialized world and now even the developing region of the world are pre-diabetic.  What does it mean? Well they have high blood sugar spikes – that rises obviously after they consume the food, the beverage and the snacks that are in market – all with the excess amount of sugar.  So our first product is just now entering that market and sending an approval in the second largest economy, in China and we have a collaborative partner in China.  It’s a major partner with financial muscle to market SUGARDOWN in China.

WSA: So what are some of the factors that you see will make Boston Therapeutics unique from some of the other players in the sector?

David Platt:  It is our impression that safety is the possibility and the possibility of the non-systemic aspect of the product will be the easiest to adopt for the first product.  The level of proof we believe we carry the message for all of the future products and the product we have in combination.  You can imagine having a better safety margin and lowering the dose of many other drug component or compound, you can see the trend not only to reduce the sugar intake but very importantly, it has shown a reduction in the insulin response that the body needs to adjust the sugar level.

WSA: So, what are some of the key goals and milestones that you’re hoping to accomplish here with the course of the next six to 12 months?

David Platt:  The first and foremost is that now we’ll be doing a capital raise to accelerate US activity and this is in all for the launch of the SUGARDOWN product.  It’s on the webpage.  Also, the execution of the IND for the FDA clinical trial that will be done on the subset of diabetic, pre-diabetic, weight loss and other sugar reduction needs, those are the milestones for the company.

WSA: So as far as investors and the financial community are concerned David, what are some of the key drivers that you wish perhaps they better understood about the company or the sector?

David Platt: Boston Therapeutics, we’ve been a quiet company in the securing of clinical founded outcomes.  There are many misconceptions in the area and we choose not to clutter that area of activity.  We have been doing our homework, of course, and doing this trial or the multiple trial to not be caught or accused of mislabeling our products.  So we believe that we truly have a very dramatic game changer of convenience and effectiveness that will be proven safe.  So the clinical trial results will come very soon and sales of SUGARDOWN in the US and China which are very large markets and finding a partner in the US to market the product as we start marketing the products, more money will come into this marketing and more partners will step forward to help us to market the product.

WSA: And perhaps you can walk us through your background and experience, David, and talk a little bit about the key management there.

David Platt:  Thank you.  I specialize in carbohydrate chemistry for many years and received my PhD in chemical engineering based from carbohydrate chemistry.  And Boston Therapeutics collaborates with professor, Kevin Mayo, from the University of Minnesota on the mechanism to block sugars in the intestines.  We are the – I believe is as far as I know that we are the only company that develop a technology to block effectively most of the sugars in the intestine.  We call non-systemic approach to blocking of the sugar.  So if the sugar blocker doesn’t go into the bloodstream, it just works in the intestine and we also have outreach for clinical trial, IND from the FDA to start a clinical trial on type 2 diabetic in dozen clinic in Boston. Boston Therapeutics is collaborating with the Sydney University Institute for their proclamation of glycemic control.  Another clinical trial site is the Chinese University of Hong Kong and the trial is complete and listed on the  So we have multiple activities, other clinical trials – we are in Dartmouth College in New Hampshire.  We published the data in a peer review journal.  So we are accumulating the foundation for our clinical trial results on safety and efficacy.

WSA: Great.  So once again, joining us today is David Platt, the CEO for Boston Therapeutics, the company trade on the OTCQB, ticker symbol BTHE.  Currently trading at about 12 cents a share market capital is around five million.  And before we conclude here David to recap some of you key points, why do you believe investors should consider the company as a good investment opportunity today?

David Platt: The results to-date in clinical trial demonstrated a potential safe and effective product to block sugar in the intestine and help weight loss problems.  The product will address the need to control sugar consumption by millions of people.  And investors should pay attention to the number of people that are in our market for this upcoming safe and effective product.

WSA: Well, we’ll certainly look forward to continue to track the company’s growth and report on your upcoming progress.  And we’d like to thank you for taking the time to join us today, David and update our investor audience on Boston Therapeutics.  It was great to have you on again.

David Platt:  Thank you very much.



About The Wall Street Analyzer 1517 Articles
The Wall Street Analyzer's staff of writers, analysts, publishers, producers, market researchers, and PR professionals aim to provide investors with the tools they need to make informed decisions on buying stock. Our staff is a mix of financial professionals and media savvy individuals whose experiences bring the best talent from both ends of the spectrum.